ArticleNature communications2018
Radionuclides transform chemotherapeutics into phototherapeutics for precise treatment of disseminated cancer.
Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04894786 (Comparison of Mulligan Internal Rotation Mobilization and Post Isometric Relaxation Technique on Pain and Function in Athletes With Glenohumeral Internal Rotation Deficit), which is not on this map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Comparison of Mulligan Internal Rotation Mobilization and Post Isometric Relaxation Technique on Pain and Function in Athletes With Glenohumeral Internal Rotation Deficit
Who cites it
40 citing papers in PubMed, 72 citations in OpenAlex.
- Cerenkov radiation modulates the extracellular matrix for improved pancreatic cancer chemotherapy.Cell biomaterials · 2026Article
- Radionuclide-stimulated dynamic therapy induces complementary immunogenic necroptosis and apoptosis cancer cell death pathways.Communications biology · 2026Article
- Illumination of Targeting Nanotherapeutics with Precision Eyes: From Optical to Radio-nanotheranostics.Theranostics · 2026Review
- Nuclear Nanomedicines: Utilization of Radiolabelling Strategies, Drug Formulation, Delivery, and Regulatory Aspects for Disease Management.Current radiopharmaceuticals · 2025Review
- Article
- Chemo-RaST with bortezomib inhibits multiple myeloma relapse.Theranostics · 2025Article
- Radionuclide-labelled nanoparticles for cancer combination therapy: a review.Journal of nanobiotechnology · 2024Review
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Investigation of Photodynamic Therapy Promoted by Cherenkov Light Activated Photosensitizers-New Aspects and Revelations.Pharmaceutics · 2024Article
- Amplification of Cerenkov luminescence using semiconducting polymers for cancer theranostics.Advanced functional materials · 2023Article
- Added Value of Scintillating Element in Cerenkov-Induced Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Psoralen as a Photosensitizers for Photodynamic Therapy by Means of In Vitro Cherenkov Light.International journal of molecular sciences · 2022Article
- In vitro and ex vivo anti-myeloma effects of nanocomposite AsScientific reports · 2022Article
- Design Principles of Hybrid Nanomaterials for Radiotherapy Enhanced by Photodynamic Therapy.International journal of molecular sciences · 2022Review
- Antiandrogen Therapy Radiosensitizes Androgen Receptor-Positive Cancers toJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Analysis of Stable Chelate-free Gadolinium Loaded Titanium Dioxide Nanoparticles for MRI-Guided Radionuclide Stimulated Cancer Treatment.Current analytical chemistry · 2022Article
- Activation of nano-photosensitizers by Y-90 microspheres to enhance oxidative stress and cell death in hepatocellular carcinoma.Scientific reports · 2022Article
- Pathogenesis and treatment of multiple myeloma.MedComm · 2022Review
- Light-Sensitive Phenacyl Crosslinked Dextran Hydrogels for Controlled Delivery.Chemistry (Weinheim an der Bergstrasse, Germany) · 2022Article
- Cerenkov radiation-activated probes for deep cancer theranostics: a review.Theranostics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Funding
Abstract
Most cancer patients succumb to disseminated disease because conventional systemic therapies lack spatiotemporal control of their toxic effects in vivo, particularly in a complicated milieu such as bone marrow where progenitor stem cells reside. Here, we demonstrate the treatment of disseminated cancer by photoactivatable drugs using radiopharmaceuticals. An orthogonal-targeting strategy and a contact-facilitated nanomicelle technology enabled highly selective delivery and co-localization of titanocene and radiolabelled fluorodeoxyglucose in disseminated multiple myeloma cells. Selective ablation of the cancer cells was achieved without significant off-target toxicity to the resident stem cells. Genomic, proteomic and multimodal imaging analyses revealed that the downregulation of CD49d, one of the dimeric protein targets of the nanomicelles, caused therapy resistance in small clusters of cancer cells. Similar treatment of a highly metastatic breast cancer model using human serum albumin-titanocene formulation significantly inhibited cancer growth. This strategy expands the use of phototherapy for treating previously inaccessible metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.